Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

Su Chu(Leukemia Research Foundation), Ravi Bhatia(University of Alabama at Birmingham), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Tinisha McDonald, David S. Snyder(City Of Hope National Medical Center), Allen Lin(Leukemia Research Foundation), Sujata Chakraborty(University of Washington)

Blood

September 20, 2011

10.1182/blood-2010-12-327437

Cited by 243

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

|Nature Genetics|2019|627

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

|Blood|2003|541

Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study

|Blood|2007|536

American Society of Clinical Oncology Statement: Achieving High-Quality Cancer Survivorship Care

|Journal of Clinical Oncology|2013|473